key: cord-0841066-bvo31flq
authors: Derespina, Kim R.; Kaushik, Shubhi; Ushay, Henry M.; Medar, Shivanand S.
title: Reply
date: 2020-11-26
journal: J Pediatr
DOI: 10.1016/j.jpeds.2020.11.046
sha: ea90fedfccf127f3a676ab9464ddb768ec57d04e
doc_id: 841066
cord_uid: bvo31flq

nan

The acute respiratory distress syndrome (ARDS) was originally described by Ashbaugh The increased incidence of PARDS correlates with an increased intubation rate in 2019 novel coronavirus infectious disease (COVID-19) that we observed compared to other respiratory viruses. We pointed out that this may be due, at least in part, to an early recommendation to limit use of noninvasive ventilation due to the risk of aerosolization of the virus. Thus, limited use of non-invasive positive pressure ventilation may have led to higher rates of endotracheal intubation and invasive mechanical ventilation thus explaining, to some extent, the higher rate of PARDS seen with COVID-19 compared to that observed with other viral infections.

Whether or not pulmonary infection with SARS-CoV-2 results in a unique or different pathophysiologic state than other respiratory viruses is yet to be elucidated. Relatively well preserved pulmonary compliance in COVID-19 ARDS has been reported by others (3, 4) and observed by us. This high compliance type of ARDS may represent a very early stage or possible differences in the pathophysiology of ARDS in COVID-19 as compared to that caused by other viral illnesses.

Additionally, a substantial proportion of patients with PARDS in our study met criteria for severe sepsis and required vasoactive support, thus indicating increased severity of illness. The presence of sepsis may be an additional risk factor for the development of PARDS and need for mechanical ventilation in this group, perhaps explaining the higher rate of PARDS in this cohort.

It is also worthy of note, though not explanatory, that the average age in our study cohort of patients who developed ARDS was 14 years, significantly higher than the average ages in the other virus studies noted by Baird, which were around 4-5 years. (5) While COVID-19 appears to confer a higher risk of PARDS in pediatric patients, mortality seems to be lower than that reported in the literature for PARDS of various etiologies; 28-day mortality in our cohort was 2.9%, whereas 90-day mortality in PARDS patients has been reported at 17% (6) . Further characterization of the pathophysiology of PARDS in COVID-19 may help explain this difference in mortality. Longer term follow-up and larger sample size will be paramount to determining the true mortality and morbidity associated with development of PARDS in children with COVID-19.

Acute respiratory distress in adults

Pediatric acute respiratory distress syndrome: consensus recommendations from the pediatric acute lung injury consensus conference

COVID-19 Lombardy ICU Network. Baseline Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

COVID-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome

Comparing the clinical severity of the first versus second wave of

Influenza A (H1N1) in a New York City pediatric healthcare facility. Pediatr Crit Care Med

Paediatric acute respiratory distress syndrome incidence and epidemiology (PARDIE): an international, observational study